RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has earned an average recommendation of “Hold” from the thirteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $9.50.

Several analysts have commented on RAPT shares. Wells Fargo & Company decreased their target price on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. UBS Group decreased their price objective on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a report on Monday, September 9th. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a research report on Monday, November 25th. JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Finally, Piper Sandler lowered RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $8.00 to $2.00 in a report on Monday, November 11th.

Institutional Trading of RAPT Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Readystate Asset Management LP bought a new position in RAPT Therapeutics in the 3rd quarter worth approximately $36,000. XTX Topco Ltd bought a new position in RAPT Therapeutics during the second quarter worth $108,000. Barclays PLC raised its stake in RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after purchasing an additional 29,195 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in RAPT Therapeutics by 8.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock valued at $148,000 after purchasing an additional 3,824 shares during the period. Finally, Los Angeles Capital Management LLC grew its position in RAPT Therapeutics by 66.2% in the 2nd quarter. Los Angeles Capital Management LLC now owns 84,586 shares of the company’s stock worth $258,000 after purchasing an additional 33,692 shares during the last quarter. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Trading Down 11.7 %

Shares of NASDAQ:RAPT opened at $0.91 on Tuesday. The firm has a market cap of $31.81 million, a price-to-earnings ratio of -0.33 and a beta of 0.07. RAPT Therapeutics has a 1 year low of $0.91 and a 1 year high of $27.35. The business has a fifty day simple moving average of $1.61 and a 200 day simple moving average of $2.35.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. On average, sell-side analysts forecast that RAPT Therapeutics will post -2.86 EPS for the current year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.